Scopolamine produces larger antidepressant and antianxiety effects in women than in men

Neuropsychopharmacology

Volumn 35, Issue 12, 2010, Pages 2479-2488

  Furey, Maura L ^a   Khanna, Ashish ^b   Hoffman, Elana M ^a   Drevets, Wayne C ^c  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b American University   (United States)

^c LAUREATE INSTITUTE FOR BRAIN RESEARCH   (United States)

Author keywords

anticholinergic; antidepressant; antimuscarinic; depression; gender

Indexed keywords

PLACEBO; SCOPOLAMINE;

ADULT; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTICLE; BIPOLAR DISORDER; BLURRED VISION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INDUCED HEADACHE; FATIGUE; FEMALE; HAMILTON ANXIETY SCALE; HEART PALPITATION; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; NERVOUSNESS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SEX DIFFERENCE; SIDE EFFECT; SINGLE BLIND PROCEDURE; TREATMENT RESPONSE; VERTIGO; XEROSTOMIA;

ADOLESCENT; ADULT; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SCOPOLAMINE; SEX CHARACTERISTICS; SINGLE-BLIND METHOD;

EID: 77958001705     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2010.131     Document Type: Article

References (55)

1. Alonso-Solis R, Abreu P, Lopez-Coviella I, Hernandez G, Fajardo N, Hernandez-Diaz F et al (1996). Gonadal steroid modulation of neuroendocrine transduction: a transynaptic view. Cell Mol Neurobiol 16: 357-382.
2. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, IV, Text Revision. American Psychiatric Association: Washington DC.
3. Bebbington PE, Dunn G, Jenkins R, Lewis G, Brugha T, Farrell M et al (1998). The influence of age and sex on the prevalence of depressive conditions: report from the National Survey of Psychiatric Morbidity. Psychol Med 28: 9-19.
4. Benmansour S, Piotrowski JP, Altamirano AV, Frazer A (2009). Impact of ovarian hormones on the modulation of the serotonin transporter by fluvoxamine. Neuropsychopharmacology 34: 555-564.
5. Berlanga C, Flores-Ramos M (2006). Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine. J Affect Disord 95: 119-123.
6. Bland RC, Orn H, Newman SC (1988). Lifetime prevalence of psychiatric disorders in Edmonton. Acta Psychiatr Scand Suppl 338: 24-32.
7. Cannon DM, Carson RE, Nugent AC, Eckelman WC, Kiesewetter DO, Williams J et al (2006). Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch Gen Psychiatry 63: 741-747.
8. Comings DE, Wu S, Rostamkhani M, McGue M, Iacono WG, MacMurray JP (2002). Association of the muscarinic cholinergic 2 receptor (CHRM2) gene with major depression in women. Am J Med Genet 114: 527-529.
9. Daniel JM, Dohanich GP (2001). Acetylcholine mediates the estrogen-induced increase in NMDA receptor binding in CA1 of the hippocampus and the associated improvement in working memory. J Neurosci 21: 6949-6956.
10. Dluzen DE, Ramirez VD (1989). Progesterone effects upon dopamine release from the corpus striatum of female rats. I. Evidence for interneuronal control. Brain Res 476: 332-337.
11. Drevets WC, Furey ML (2010). Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry 67: 432-438.
12. Drevets WC, Price JL, Furey ML (2008). Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct 213: 93-118.
13. First MB, Spitzer RL, Gibbon M, Williams JBW (1997). Structured Clinical Interview for DSM-IV. American Psychiatric Press: Washington, DC.
14. Frackiewicz EJ, Sramek JJ, Cutler NR (2000). Gender differences in depression and antidepressant pharmacokinetics and adverse events. Ann Pharmacother 34: 80-88.
15. Furey ML, Drevets WC (2006). Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry 63: 1121-1129.
16. Gibbs RB, Gabor R, Cox T, Johnson DA (2004). Effects of raloxifene and estradiol on hippocampal acetylcholine release and spatial learning in the rat. Psychoneuroendocrinology 29: 741-748.
17. Goodnick PJ, Chaudry T, Artadi J, Arcey S (2000). Women's issues in mood disorders. Expert Opin Pharmacother 1: 903-916.
18. Gupta S, Mehrotra S, Villalon C, De Vries R, Garrelds I, Saxena P et al (2007). Effects of female sex hormones on responses to CGRP, acetylcholine, and 5-HT in rat isolated arteries. Headache 47: 564-575.
19. Hamilton M (1959). The assessment of anxiety states by rating. Br J Med Psychol 32: 50-55.
20. Hartvig P, Nordberg A, Torstenson R, Sjoberg P, Fasth KJ, Langstrom B (2002). Interaction of a muscarinic cholinergic agonist on acetylcholine and dopamine receptors in the monkey brain studied with positron emission tomography. Dement Geriatr Cogn Disord 13: 199-204.
21. Hildebrandt MG, Steyerberg EW, Stage KB, Passchier J, Kragh-Soerensen P (2003). Are gender differences important for the clinical effects of antidepressants? Am J Psychiatry 160: 1643-1650.
22. Janowsky DS, el-Yousef MK, Davis JM, Sekerke HJ (1972). A cholinergic-adrenergic hypothesis of mania and depression. Lancet 2: 632-635.
23. Janowsky DS, Overstreet DH (1990). Cholinergic dysfunction in depression. Pharmacol Toxicol 66(Suppl 3): 100-111.
24. Janowsky DS, Overstreet DH, Nurnberger Jr JI (1994). Is cholinergic sensitivity a genetic marker for the affective disorders? Am J Med Genet 54: 335-344.
25. Janowsky DS, Risch SC, Gillin JC (1983). Adrenergic-cholinergic balance and the treatment of affective disorders. Prog Neurop-sychopharmacol Biol Psychiatry 7: 297-307.
26. Khan A, Khan SR, Shankles EB, Polissar NL (2002). Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials. Int Clin Psychopharmacol 17: 281-285.
27. Kornstein SG, Schatzberg AF, Thase ME, Yonkers KA, McCullough JP, Keitner GI et al (2000). Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 157: 1445-1452.
28. Labrie F, Ferland L, Veilleux R, Euvrard C, Boissier J (1980). Influence of estrogens on tuberoinfundibular and striatal dopa-minergic systems in the rat. Acta Psychiatr Belg 80: 658-673.
29. Lester DB, Rogers TD, Blaha CD (2010). Acetylcholine-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 16: 137-162.
30. Liu HF, Zhou WH, Xie XH, Cao JL, Gu J, Yang GD (2004). [Muscarinic receptors modulate the mRNA expression of NMDA receptors in brainstem and the release of glutamate in periaqueductal grey during morphine withdrawal in rats]. Sheng Li Xue Bao 56: 95-100.
31. Martenyi F, Dossenbach M, Mraz K, Metcalfe S (2001). Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. Eur Neuropsychopharmacol 11: 227-232.
32. McEwen B, Akama K, Alves S, Brake WG, Bulloch K, Lee S et al (2001). Tracking the estrogen receptor in neurons: implications for estrogen-induced synapse formation. Proc Natl Acad Sci USA 98: 7093-7100.
33. McNair DM, Lorr M, Droppleman LF (1971). EITS Manual for the Profile of Mood States. Educational and Industrial Testing Service: San Diego, CA.
34. Nierenberg AA, DeCecco LM (2001). Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry 62(Suppl 16): 5-9.
35. Overstreet DH, Daws LC, Schiller GD, Orbach J, Janowsky DS (1998). Cholinergic/serotonergic interactions in hypothermia: implications for rat models of depression. Pharmacol Biochem Behav 59: 777-785.
36. Overstreet DH, Miller CS, Janowsky DS, Russell RW (1996). Potential animal model of multiple chemical sensitivity with cholinergic supersensitivity. Toxicology 111: 119-134.
37. Paul IA, Skolnick P (2003). Glutamate and depression: clinical and preclinical studies. Ann NY Acad Sci 1003: 250-272.
38. Pinto-Meza A, Usall J, Serrano-Blanco A, Suarez D, Haro JM (2006). Gender differences in response to antidepressant treatment prescribed in primary care. Does menopause make a difference? J Affect Disord 93: 53-60.
39. Pongrac JL, Gibbs RB, Defranco DB (2004). Estrogen-mediated regulation of cholinergic expression in basal forebrain neurons requires extracellular- signal-regulated kinase activity. Neu-roscience 124: 809-816.
40. Quitkin FM, Stewart JW, McGrath PJ (2001). Gender differences in treatment response. Am J Psychiatry 158: 1531-1533.
41. Riemann D, Hohagen F, Bahro M, Berger M (1994a). Sleep in depression: the influence of age, gender and diagnostic subtype on baseline sleep and the cholinergic REM induction test with RS 86. Eur Arch Psychiatry Clin Neurosci 243: 279-290.
42. Riemann D, Hohagen F, Krieger S, Gann H, Muller WE, Olbrich R et al (1994b). Cholinergic REM induction test: muscarinic supersensitivity underlies polysomnographic findings in both depression and schizophrenia. J Psychiatr Res 28: 195-210.
43. Rubin RT, Abbasi SA, Rhodes ME, Czambel RK (2003). Growth hormone responses to low-dose physostigmine administration: functional sex differences (sexual diergism) between major depressives and matched controls. Psychol Med 33: 655-665.
44. Rubin RT, O'Toole SM, Rhodes ME, Sekula LK, Czambel RK (1999). Hypothalamo-pituitary-adrenal cortical responses to low-dose physostigmine and arginine vasopressin administration: sex differences between major depressives and matched control subjects. Psychiatry Res 89: 1-20.
45. Rubinow DR, Schmidt PJ, Roca CA (1998). Estrogen-serotonin interactions: implications for affective regulation. Biol Psychiatry 44: 839-850.
46. Sarter M, Bruno JP, Turchi J (1999). Basal forebrain afferent projections modulating cortical acetylcholine, attention, and implications for neuropsychiatric disorders. Ann NY Acad Sci 877: 368-382.
47. Sell SL, Craft RM, Seitz PK, Stutz SJ, Cunningham KA, Thomas ML (2008). Estradiol-sertraline synergy in ovariectomized rats. Psychoneuroendocrinology 33: 1051-1060.
48. Smith CC, Vedder LC, McMahon LL (2009). Estradiol and the relationship between dendritic spines, NR2B containing NMDA receptors, and the magnitude of long-term potentiation at hippocampal CA3-CA1 synapses. Psychoneuroendocrinology 34(Suppl 1): S130-S142.
49. Steiner M, Dunn E, Born L (2003). Hormones and mood: from menarche to menopause and beyond. J Affect Disord 74: 67-83.
50. Thompson TL, Certain ME (2005). Estrogen mediated inhibition of dopamine transport in the striatum: regulation by G alpha i/o. Eur J Pharmacol 511: 121-126.
51. Wang JC, Hinrichs AL, Stock H, Budde J, Allen R, Bertelsen S et al (2004). Evidence of common and specific genetic effects: association of the muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol dependence and major depressive syndrome. Hum Mol Genet 13: 1903-1911.
52. Woolley CS, McEwen BS (1994). Estradiol regulates hippocampal dendritic spine density via an N-methyl-D-aspartate receptor-dependent mechanism. J Neurosci 14: 7680-7687.
53. Yonkers KA (2003). Special issues related to the treatment of depression in women. J Clin Psychiatry 64(Suppl 18): 8-13.
54. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978). A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133: 429-435.
55. Zhang Z, Chen K, Shih JC, Teng CT (2006). Estrogen-related receptors-stimulated monoamine oxidase B promoter activity is down-regulated by estrogen receptors. Mol Endocrinol 20: 1547-1561.